Ebg Medaustron Gmbh
Clinical trials sponsored by Ebg Medaustron Gmbh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Proton therapy combo aims to shrink pancreatic tumors before surgery Results expected Dec 2026 (estimated)
-
Proton therapy combo aims to shrink pancreatic tumors before surgery
Disease control Recruiting nowThis study tests a new approach for people with borderline resectable pancreatic cancer, where the tumor is close to important blood vessels but may still be removable. Participants first receive chemotherapy, then proton beam radiation combined with more chemo, followed by surge…
Sponsor: EBG MedAustron GmbH • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New radiation approach aims to shrink pancreatic tumors in just five sessions
Disease control Recruiting nowThis study tests a short, high-dose radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The treatment uses protons or carbon ions to deliver a precise, powerful dose in only five sessions. Researchers hope this approach will imp…
Sponsor: EBG MedAustron GmbH • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New registry to monitor ion beam therapy results
Knowledge-focused Recruiting nowThis registry study is collecting data from 2,800 cancer patients treated with ion beam therapy (protons and carbon ions) at MedAustron. Researchers will track tumor response, survival, side effects, and quality of life over time. The goal is to better understand the real-world b…
Sponsor: EBG MedAustron GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC